Microbot Medical (MBOT) to Release Quarterly Earnings on Tuesday

Microbot Medical (NASDAQ:MBOT) is projected to post its results before the market opens on Tuesday, March 24th. Analysts expect Microbot Medical to post earnings of ($0.06) per share and revenue of $0.1130 million for the quarter.

Microbot Medical Stock Down 2.7%

MBOT opened at $2.54 on Monday. The firm has a market capitalization of $170.59 million, a P/E ratio of -5.64 and a beta of 1.22. The firm’s 50 day moving average is $2.21 and its 200-day moving average is $2.45. Microbot Medical has a 52-week low of $1.35 and a 52-week high of $4.67.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Microbot Medical in a report on Friday, November 28th. Roth Mkm initiated coverage on shares of Microbot Medical in a report on Wednesday, December 3rd. They issued a “buy” rating and a $5.50 price objective on the stock. Finally, B. Riley Financial began coverage on shares of Microbot Medical in a research report on Tuesday, February 10th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

Hedge Funds Weigh In On Microbot Medical

Several institutional investors and hedge funds have recently made changes to their positions in MBOT. Virtu Financial LLC bought a new stake in shares of Microbot Medical in the fourth quarter worth $117,000. Invesco Ltd. bought a new position in Microbot Medical during the 4th quarter valued at $49,000. XTX Topco Ltd bought a new position in Microbot Medical during the 4th quarter valued at $63,000. Man Group plc acquired a new position in Microbot Medical during the 4th quarter worth $35,000. Finally, Bridgeway Capital Management LLC acquired a new position in Microbot Medical during the 4th quarter worth $222,000. 16.30% of the stock is currently owned by hedge funds and other institutional investors.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.